# A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

> **NCT05256381** · PHASE2 · TERMINATED · sponsor: **SOTIO Biotech AG** · enrollment: 166 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Cutaneous Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Castration-resistant Prostate Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Nanrilkefusp Alfa
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05256381
- **Lead sponsor:** SOTIO Biotech AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-21
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-11-29
- **Target enrollment:** 166 (ACTUAL)
- **Why stopped:** Due to lack of expected efficacy shown at the time of the interim analysis
- **Last updated:** 2025-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256381, "A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05256381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*